Metabolic Diseases Impair Millions of Lives

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly non-alcoholic fatty liver disease - NAFLD) and its progressive stage metabolic dysfunction-associated steatohepatitis (MASH, formerly non-alcoholic steatohepatitis - NASH) represent a leading cause of liver-related morbidity and mortality in the U.S. and worldwide. Given the high prevalence and rapid growth of MASLD, the economic and health burden, and MASH-associated morbidity and mortality, there is an unmet medical need for therapies that can stop, slow, or reverse the progression of MASLD. Adipose tissue plays a key role in metabolic health and MASLD pathogenesis through its regulation of energy metabolism and endocrine function.  

​

Britecyte is developing an engineered adipose therapy that targets disrupted metabolism in adipose tissue, the root cause of MASH.

​

Britecyte’s effort to develop a novel adipose-based therapy for MASH was supported by the Maryland Stem Cell Research Fund (MSCRF) Commercialization Grant (2022-MSCRFCO-5921). With support of the MSCRF, Britecyte progressed to the late stages of preclinical development. Preclinical results are summarized in a peer-reviewed manuscript published in Frontiers in Bioengineering and Biotechnology.

​

Additional preclinical studies to optimize the therapeutic formulation and treatment regimen are ongoing.

​